We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Adverum Biotechnologies Inc | NASDAQ:ADVM | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.43 | 4.30% | 10.43 | 9.75 | 44.43 | 10.69 | 10.00 | 10.10 | 900,531 | 05:00:01 |
From May 2019 to May 2024
American Society of Gene and Cell Therapy (ASGCT) Virtual Annual Meeting 2020Abstracts are available online and presentations and posters can be accessed through ASGCT’s website on May 12, 2020 at www.asgct.org.
Abstract Title (Oral): ADVM-022 Intravitreal Gene Therapy for Neovascular AMD - Results from the Phase 1 OPTIC Study Session: AAV Vectors - Clinical Studies IIDate/Time: Wednesday, May 13, 2020, 4:00 - 4:15 pm EDTSpeaker: Szilárd Kiss, M.D., Director of Clinical Research in the Department of Ophthalmology at Weill Cornell Medical Group
Abstract Title (Poster): Proof-of-Concept Studies in Mongolian Gerbils Support Intravitreal Gene Replacement Therapy of Human L-Opsin for Blue Cone MonochromacySession: AAV Vectors - Preclinical and Proof-of-Concept StudiesDate/Time: Wednesday, May 13, 2020, 5:30 - 6:30 pm EDT
Abstract Title (Poster): Large Scale Suspension Production of AAV Capsid Variant Libraries from Stable Recombinant HEK293 Cell BanksSession: Vector and Cell Engineering, Production or ManufacturingDate/Time: Tuesday May 12, 2020, 5:30 - 6:30 pm EDT
Association for Vision and Ophthalmology (ARVO)The ARVO 2020 Annual Meeting has been cancelled and video-recorded presentations will be available online on ARVOLearn beginning May 16, 2020. Additionally, abstracts will be published in the journal Investigative Ophthalmology & Vision Science (IOVS) no later than July 31, 2020.
Abstract Title: Intravitreal Delivery of AAV2.7m8. Ranibizumab Suppresses Exudative Lesions in the NHP Laser Induced Model of nAMD
Abstract Title: Mouse Studies Support Intravitreal Gene Therapy for Blue Cone Monochromacy
About Adverum BiotechnologiesAdverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration. For more information, please visit www.adverum.com.
Investor and Media Inquiries:
Investors:Myesha LacyAdverum Biotechnologies, Inc.mlacy@adverum.com1-650-649-1257
Media:Cherilyn Cecchini, M.D.LifeSci Communicationsccecchini@lifescicomms.com1-646-876-5196
1 Year Adverum Biotechnologies Chart |
1 Month Adverum Biotechnologies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
